All stocks / BCLI
BRAINSTORM CELL THERAPEUTICS INC. BCLI
Brainstorm Cell Therapeutics (BCLI): shares outstanding up 29% in a year, convertible notes mentioned in an 8-K in January 2026 and the latest annual figures in plain language. Each fact links to its SEC filing.
Market listing
- Full name
- BRAINSTROM CELL THERAPEUTICS
- Market tier
- OTCQB
- Trading status
- Active
- Last trade
- Nov 16
- Website
- www.brainstorm-cell.com
News headlines
The financial report, and what it means
Annual figures to 2025-12-31- Net loss
- ($10,307,000)
It spends more than it earns
Under strainThe company lost $10.3 million in the year. It reported no sales.
- Cash and cash equivalents
- $29,000
- Net cash used in operating activities
- ($6,975,000)
The cash could run out soon
Under strainIt had $29,000 in the bank and used about $581,250 a month. At that pace the money lasts less than a month unless it borrows or sells more shares.
- Total assets
- $1,022,000
- Total liabilities
- $11,007,000
It owes more than it owns
Under strainEverything the company owns adds up to $1 million. Its debts and unpaid bills add up to $11 million. That is about $10.77 owed for every $1 owned.
What this adds up to
3 of 3 checks show strain. It spends more than it earns. The cash could run out soon. It owes more than it owns. These are facts from the company's own reports, not a recommendation.
Signals
Shares outstanding rose from 11,034,775 (2025-11-11) to 14,259,377 (2026-11-11), up 29%.
Rule: Shares outstanding up 20% or more in 12 months. Source record
Estimated float about 11,390,773 shares as of 2026-11-11: 14,259,377 outstanding minus 2,868,604 held by 5 reporting insider(s).
Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record
8-K filed 2026-01-09 mentions: convertible note.
Rule: 8-K in the last 12 months mentioning convertible notes or an equity line. Source record
Shares outstanding
Source: SEC filingsPrice chart
Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets
Recent filings
Common questions about BCLI
Does BCLI file reports with the SEC?
Yes. Brainstorm Cell Therapeutics files with the SEC under company number 0001137883. The most recent filing we hold is a 8-K dated 2026-11-16.
Source recordHow many BCLI shares are outstanding?
14,259,377 shares as of 2026-11-11, as reported to the SEC. That is up 29% from 11,034,775 on 2025-11-11.
Source recordHas BCLI filed reports late?
We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.
Who runs Brainstorm Cell Therapeutics?
Officers named in its insider filings: Chaim Lebovits (President & CEO), Alla Patlis (See Remarks) and Peter Joe Pitts (Executive Chairman).
Source recordIs Brainstorm Cell Therapeutics making money?
The company lost $10.3 million in the year. It reported no sales. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)
Source record